Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibiotics for Seronegative Chronic Lyme Disease
NCT00000938Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ceftriaxone and doxycycline in Lyme disease (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Efficacy in eliminating symptoms at 90 days. Status: completed.
02
Drugs
ceftriaxonedoxycycline
03
Conditions
Lyme disease
Beyond the preview
Go deeper on NCT00000938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000938.